Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET
Company Participants
Ryan Asay - VP of Corporate Affairs
David Meek - CEO
Charles Baum - President, Founder and Head of R&D
Laurie Stelzer - CFO
James Christensen - Chief Scientific Officer
Ben Hickey - Chief Commercial Officer
Alan Sandler - Chief Medical Officer
Conference Call Participants
Tyler Van Buren - Cowen and Company
Salveen Richter - Goldman Sachs
Harshita Polishetty - Barclays
Jonathan Miller - Evercore ISI
Michael Schmidt - Guggenheim
Neil Carnahan - Stifel
Noah Burhance - JPMorgan
Jason Gerberry - Bank of America
Michael Ulz - Morgan Stanley
Yigal Nochomovitz - Citigroup
Maury Raycroft - Jefferies
Evan Seigerman - BMO
Ami Fadia - Needham
Andrew Fleszar - B. Riley Securities
Jay Olson - Oppenheimer
Operator
Good afternoon and welcome to the Mirati Therapeutics Fourth Quarter 2022 Earnings Call. My name is Cynthia and I'll be the operator for today's call. [Operator Instructions]
It is my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.
Ryan Asay
Thank you. Cynthia and welcome everyone to this afternoon's call. Joining me on the call today are David Meek, our Chief Executive Officer; Dr. Chuck Baum, our President, Founder and Head of Research and Development; Dr. Alan Sandler, our Chief Medical Officer; Dr. Jamie Christensen, our Chief Scientific Officer; Ben Hickey, our Chief Commercial Officer; Laurie Stelzer, our Chief Financial Officer.
Before we begin, I would like to inform you that certain statements we make during this call will be forward looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K that's filed with the US Securities and Exchange Commission.
This afternoon, we released financial results for the fourth quarter and full year ended December 31, 2022 and recent corporate updates. This press release is available in the Investors section of our website at mirati.com.
With that, David, I'll turn the call over to you.
David Meek
Thank you. Ryan, and thank you for joining us on the call today.
2022 was a transformational year for Mirati and I'm pleased to report we received our first approval and launched our first commercial product, KRAZATI for KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer. We deployed our highly experienced lung cancer commercial field force and made significant progress advancing our differentiated pipeline of targeted oncology products.